Alpha Fetoprotein - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Alpha Fetoprotein

The Experts below are selected from a list of 156 Experts worldwide ranked by ideXlab platform

Yinghuang Tsai – 1st expert on this subject based on the ideXlab platform

  • Alpha Fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis
    The American Journal of Gastroenterology, 2015
    Co-Authors: Te Sheng Chang, Yu Chih Wu, Shui Yi Tung, Yung Yu Hsieh, Hao Chun Huang, Weiming Chen, Chien Heng Shen, Chang Hsien Lu, Cheng Shyong Wu, Yinghuang Tsai

    Abstract:

    AlphaFetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis

Shigenobu Nagataki – 2nd expert on this subject based on the ideXlab platform

  • early recognition of hepatocellular carcinoma based on altered profiles of Alpha Fetoprotein
    The New England Journal of Medicine, 1993
    Co-Authors: Yoshiaki Sato, Kazuhisa Taketa, Y. Endo, Keisuke Nakata, Yuji Kato, Masayoshi Shima, Nobuko Ishii, Toshihiko Koji, Shigenobu Nagataki

    Abstract:

    Background The sugar-chain structures of circulating AlphaFetoprotein in patients with hepatocellular carcinomas differ from those in patients with cirrhosis. We studied the reactivity of AlphaFetoprotein with two lectins, Lens culinaris agglutinin A and erythroagglutinating phytohemagglutinin, to monitor the evolution of hepatocellular carcinoma in patients with cirrhosis. Methods Among 361 patients with cirrhosis caused mainly by chronic hepatitis B or hepatitis C virus infection, 33 with base-line serum AlphaFetoprotein concentrations ≥ 30 ng per milliliter were found to have hepatocellular carcinomas during a mean follow-up of 35 months. The lectin-reactive profiles of the AlphaFetoprotein in the serum of these 33 patients were analyzed and compared with those in the serum of 32 patients with cirrhosis who had increased base-line serum AlphaFetoprotein concentrations and were followed for at least 24 months but in whom hepatocellular carcinoma did not develop. Results At the time of tumor detecti…

Yoshiro Matsumoto – 3rd expert on this subject based on the ideXlab platform

  • clinicopathologic features of gastric cancers producing Alpha Fetoprotein
    Digestive Surgery, 2002
    Co-Authors: Koji Kono, Hideki Amemiya, Takayoshi Sekikawa, Hidehiko Iizuka, Akihiro Takahashi, Hideki Fujii, Yoshiro Matsumoto

    Abstract:

    Background: Patients with gastric cancers producing AlphaFetoprotein (AFP) were reported to have a poor prognosis with high rates of liver metastasis. The purpose of the present st